Prasugrel — CAS 150322-43-3

Prasugrel is a thienopyridine antiplatelet agent that irreversibly inhibits the P2Y12 receptor on platelets, thereby preventing ADP-mediated platelet aggregation. It is used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI). Mediocon Inc manufactures Prasugrel API at its GMP-certified facility in Aurangabad, Maharashtra, India.

• Reduction of atherothrombotic events in acute coronary syndrome (ACS)
• Used alongside aspirin in dual antiplatelet therapy post-PCI
• Management of unstable angina and non-ST-elevation myocardial infarction
• Prevention of stent thrombosis after coronary stent placement

• GMP Certified manufacturing facility in Aurangabad, Maharashtra, India
• Full pharmacopoeial compliance: IP / BP / USP standards
• Complete documentation: Certificate of Analysis (CoA), MSDS, Certificate of Origin
• Stringent in-process quality control at every manufacturing stage
• HPLC purity testing and spectroscopic identification (IR, NMR)
• Cold-chain and controlled-environment storage facilities available
• Exported to 40+ countries with full regulatory support